| Title |
Personalized cancer vaccines: adjuvants are important, too
|
|---|---|
| Published in |
Cancer Immunology, Immunotherapy, April 2018
|
| DOI | 10.1007/s00262-018-2158-4 |
| Pubmed ID | |
| Authors |
Cécile Gouttefangeas, Hans-Georg Rammensee |
| Abstract |
Therapeutic cancer vaccines have shown limited clinical efficacy so far. Nevertheless, in the meantime, our understanding of immune cell function and the interactions of immune cells with growing tumors has advanced considerably. We are now in a position to invest this knowledge into the design of more powerful vaccines and therapy combinations aimed at increasing immunogenicity and decreasing tumor-induced immunosuppression. This review focuses essentially on peptide-based human vaccines. We will discuss two aspects that are critical for increasing their intrinsic immunogenicity: the selection of the antigen(s) to be targeted, and the as yet unmet need for strong adjuvants. |
Mendeley readers
The data shown below were compiled from readership statistics for 70 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 70 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 13 | 19% |
| Student > Ph. D. Student | 9 | 13% |
| Researcher | 9 | 13% |
| Student > Master | 9 | 13% |
| Professor | 5 | 7% |
| Other | 11 | 16% |
| Unknown | 14 | 20% |
| Readers by discipline | Count | As % |
|---|---|---|
| Immunology and Microbiology | 14 | 20% |
| Biochemistry, Genetics and Molecular Biology | 10 | 14% |
| Agricultural and Biological Sciences | 10 | 14% |
| Medicine and Dentistry | 9 | 13% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 6% |
| Other | 8 | 11% |
| Unknown | 15 | 21% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 13 April 2023.
All research outputs
#7,831,841
of 23,760,369 outputs
Outputs from Cancer Immunology, Immunotherapy
#1,066
of 2,889 outputs
Outputs of similar age
#133,218
of 330,588 outputs
Outputs of similar age from Cancer Immunology, Immunotherapy
#13
of 29 outputs
Altmetric has tracked 23,760,369 research outputs across all sources so far. This one is in the 44th percentile – i.e., 44% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,889 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.3. This one is in the 35th percentile – i.e., 35% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 330,588 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 53% of its contemporaries.
We're also able to compare this research output to 29 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 55% of its contemporaries.